Evogene - Asset Resilience Ratio
Evogene (EVGN) has an Asset Resilience Ratio of 39.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Evogene working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Evogene's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Evogene (EVGN) total assets.
Liquid Assets Composition Over Time
This chart breaks down Evogene's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Evogene (EVGN) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA10.33 Million | 39.61% |
| Total Liquid Assets | ILA10.33 Million | 39.61% |
Asset Resilience Insights
- Very High Liquidity: Evogene maintains exceptional liquid asset reserves at 39.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Evogene Industry Peers by Asset Resilience Ratio
Compare Evogene's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Upstream Bio, Inc.
NASDAQ:UPB |
Biotechnology | 64.70% |
Annual Asset Resilience Ratio for Evogene (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Evogene.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.03% | ILA10.00K ≈ $26.81 |
ILA39.86 Million ≈ $106.87K |
-20.11pp |
| 2023-12-31 | 20.14% | ILA10.29 Million ≈ $27.59K |
ILA51.10 Million ≈ $137.00K |
+8.78pp |
| 2022-12-31 | 11.36% | ILA6.38 Million ≈ $17.09K |
ILA56.13 Million ≈ $150.47K |
-16.87pp |
| 2021-12-31 | 28.23% | ILA21.54 Million ≈ $57.75K |
ILA76.30 Million ≈ $204.57K |
+25.45pp |
| 2020-12-31 | 2.78% | ILA2.00 Million ≈ $5.36K |
ILA71.92 Million ≈ $192.80K |
-14.21pp |
| 2019-12-31 | 16.99% | ILA12.13 Million ≈ $32.51K |
ILA71.36 Million ≈ $191.32K |
-65.90pp |
| 2018-12-31 | 82.90% | ILA48.66 Million ≈ $130.45K |
ILA58.69 Million ≈ $157.36K |
-5.14pp |
| 2017-12-31 | 88.04% | ILA68.32 Million ≈ $183.16K |
ILA77.60 Million ≈ $208.05K |
-0.39pp |
| 2016-12-31 | 88.42% | ILA84.88 Million ≈ $227.55K |
ILA95.99 Million ≈ $257.34K |
+8.13pp |
| 2015-12-31 | 80.30% | ILA90.41 Million ≈ $242.39K |
ILA112.59 Million ≈ $301.86K |
-5.99pp |
| 2014-12-31 | 86.28% | ILA110.09 Million ≈ $295.14K |
ILA127.59 Million ≈ $342.05K |
+63.38pp |
| 2013-12-31 | 22.91% | ILA31.45 Million ≈ $84.32K |
ILA137.31 Million ≈ $368.13K |
-24.69pp |
| 2012-12-31 | 47.60% | ILA30.87 Million ≈ $82.76K |
ILA64.86 Million ≈ $173.87K |
-29.48pp |
| 2011-12-31 | 77.07% | ILA52.32 Million ≈ $140.28K |
ILA67.89 Million ≈ $182.01K |
+17.06pp |
| 2010-12-31 | 60.01% | ILA25.73 Million ≈ $68.98K |
ILA42.87 Million ≈ $114.94K |
+31.97pp |
| 2009-12-31 | 28.04% | ILA12.02 Million ≈ $32.24K |
ILA42.88 Million ≈ $114.96K |
-15.80pp |
| 2008-12-31 | 43.84% | ILA14.88 Million ≈ $39.90K |
ILA33.95 Million ≈ $91.01K |
+38.48pp |
| 2007-12-31 | 5.36% | ILA572.00K ≈ $1.53K |
ILA10.67 Million ≈ $28.60K |
-33.08pp |
| 2006-12-31 | 38.44% | ILA7.50 Million ≈ $20.12K |
ILA19.52 Million ≈ $52.34K |
-- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more